SNMMI Releases Executive Summary from FDA Stakeholder Meeting

May 20, 2015

SNMMI finalized its executive summary of the broad FDA Stakeholder meeting held in the fall of 2014. The meeting goal was to facilitate the approval of new radiopharmaceuticals and their great potential to sustain the field of nuclear medicine and molecular imaging, and more importantly, to translate these agents' promise to clinical care. The meeting brought together representatives of academic medicine, industry, government agencies, and professional societies.

Meeting participants discussed four topics related to the meeting goal. The executive summary summarizes the discussions held and offers recommendations provided by meeting participants. 

  • Market/commercialization barriers
  • Strategies to improve the current approval process
  • Possible new pathways
  • Outcome measures for FDA and CMS

Read the Executive Summary here.